Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.

@article{Quirt1991ImprovedSI,
  title={Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.},
  author={I. C. Quirt and W E Shelley and Joseph L. Pater and Audley J. Bodurtha and P. B. McCulloch and Tom McPherson and Alexander H. G. Paterson and Ross Prentice and Hulbert K. B. Silver and Andrew R. Willan},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 5},
  pages={729-35}
}
Five hundred forty-three patients with completely resected malignant melanoma who were considered to have a significant risk of developing recurrent disease were randomized to one of four study groups. One group received levamisole 2.5 mg/kg on 2 consecutive days weekly for 3 years, a second group received bacillus Calmette-Guérin (BCG) for 3 years. A third group alternated 8-week courses of BCG and levamisole for 3 years and a fourth group underwent clinical assessment at the same frequency as… CONTINUE READING